Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
Pediatric cancer care comprises a rapidly evolving field across solid and hematologic malignancies. Advances in treatment strategies—including chemotherapeutic, immunotherapeutic, and targeted agents—have changed the landscape and expanded the arsenal of available agents for treating pediatric patients. Novel techniques to detect and characterize tumors have further created new opportunities to improve outcomes in pediatric and adolescent/young adult patients with cancer.
This virtual educational congress features expert updates and interpretation of clinical trial data across various tumor subspecialties pertinent to pediatric cancer. Attendees will have the opportunity to learn about emerging therapeutics, novel approaches with currently available agents, ongoing clinical trials, and other clinically relevant developments in pediatric oncology care.
This educational activity is an archive of the live virtual
symposium held on November 7, 2025.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Examine the utilization of biomarkers and emerging actionable targets in various pediatric malignancies to guide treatment decisions
- Explore the most recent findings from clinical trials, encompassing immunotherapy, targeted therapy, and/or chemotherapy in the realm of pediatric oncology
- Implement optimal approaches for recognizing and addressing potential adverse events linked to pediatric anticancer therapies
- Identify effective management approaches for pediatric patients with cancer in a broad range of clinical scenarios
Jacqueline M. Kraveka, DO
Professor of Pediatrics
Institutional COG Principal Investigator
Institutional BCC Principal Investigator
MUSC Shawn Jenkins Children’s Hospital
Medical University of South Carolina
Hollings Cancer Center—A National Cancer Institute Designated Cancer Center
Division of Pediatric Hematology-Oncology
Charleston, SC
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: US WorldMeds, Y-mAbs Therapeutics; Grant Research/Funding: Y-mAbs Therapeutics
For more information about the faculty and disclosures, please click here.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here